Analytical Data
-
Gene name
SGCB
- Application
-
Alternative Names
SGCB;Beta-sarcoglycan
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16585
-
Expression Region
1-318aa
-
AA Sequence
MAAAAAAAAEQQSSNGPVKKSMREKAVERRSVNKEHNSNFKAGYIPIDED RLHKTGLRGRKGNLAICVIILLFILAVINLIITLVIWAVIRIGPNGCDSM EFHESGLLRFKQVSDMGVIHPLYKSTVGGRRNENLVITGNNQPIVFQQGT TKLSVENNKTSITSDIGMQFFDPRTQNILFSTDYETHEFHLPSGVKSLNV QKASTERITSNATSDLNIKVDGRAIVRGNEGVFIMGKTIEFHMGGNMELK AENSIILNGSVMVSTTRLPSSSSGDQLGSGDWVRYKLCMCADGTLFKVQV TSQNMGCQISDNPCGNTH
-
Molecular Weight
61 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCB (Sarcoglycan Beta) is a member of the sarcoglycan complex, which plays a crucial role in the structural integrity and function of muscle tissue. Research into SGCB has gained significant attention due to its association with various forms of muscular dystrophy, particularly limb-girdle muscular dystrophy type 2E (LGMD2E). Mutations in the SGCB gene can lead to the destabilization of the dystrophin-associated protein complex, resulting in muscle fiber damage and progressive muscle weakness. Understanding the molecular mechanisms underlying SGCB dysfunction is essential for identifying potential therapeutic strategies. Recent advances in gene therapy, protein replacement, and CRISPR-Cas9 technology have opened new avenues for addressing SGCB-related muscle disorders. Investigating the structure-function relationship of SGCB, its interactions with other components of the sarcoglycan complex, and its role in muscle cell signaling pathways can provide insights into the pathophysiology of muscular dystrophies. Additionally, animal models and patient-derived cell lines are being increasingly utilized to study SGCB's function and the impact of specific mutations, facilitating the development of targeted treatments. Therefore, ongoing research into SGCB not only enhances our understanding of muscle biology but also holds promise for innovative therapeutic interventions in muscle degenerative diseases.
